VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 12,400 shares, a decrease of 63.4% from the February 29th total of 33,900 shares. Based on an average daily volume of 117,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.1% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VYNE. Eventide Asset Management LLC bought a new stake in shares of VYNE Therapeutics in the 4th quarter worth $3,249,000. Citadel Advisors LLC purchased a new position in VYNE Therapeutics during the fourth quarter valued at $2,752,000. Parkman Healthcare Partners LLC purchased a new position in VYNE Therapeutics during the fourth quarter valued at $1,623,000. Palo Alto Investors LP purchased a new position in VYNE Therapeutics during the fourth quarter valued at $1,038,000. Finally, Millennium Management LLC lifted its position in VYNE Therapeutics by 145.6% during the fourth quarter. Millennium Management LLC now owns 488,012 shares of the company’s stock valued at $73,000 after purchasing an additional 289,298 shares in the last quarter. Institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Stock Performance

Shares of NASDAQ:VYNE opened at $2.96 on Thursday. VYNE Therapeutics has a 52-week low of $1.67 and a 52-week high of $8.73. The firm has a market capitalization of $41.74 million, a P/E ratio of -0.42 and a beta of 1.18. The stock has a 50 day moving average price of $2.13 and a 200-day moving average price of $2.76.

VYNE Therapeutics (NASDAQ:VYNE) last announced its earnings results on Thursday, February 29th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.30. VYNE Therapeutics had a negative return on equity of 77.46% and a negative net margin of 6,710.38%. The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.15 million. On average, equities analysts forecast that VYNE Therapeutics will post -1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $5.75 target price on shares of VYNE Therapeutics in a report on Thursday, February 29th.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.